LIGHTBEAM-U01-Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors.

Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

Part 1: Number of Participants from 1 to <18 years of Age Who Experience a Dose-Limiting Toxicity (DLT), Part 1: Number of Participants from 1 to <18 years of Age Who Experience One or More Adverse Events (AEs), Part 1: Number of Participants from 1 to <18 years of Age Who Discontinue Study Treatment Due to AEs, Part 1: Number of Participants from 1 to <18 years of Age Who Receive Dose Modification Due to AEs, Part 1 and Part 2: Objective Response (OR) for Participants with B-Cell Acute Lymphoblastic Leukemia (B-ALL), Part 1 and Part 2: OR for Participants with Diffuse Large B-Cell Lymphoma (DLBCL)/Burkitt Lymphoma, Neuroblastoma, and Ewing Sarcoma

Part 1 and Part 2: Area Under the Curve (AUC) of Total Antibody, Part 1 and Part 2: Maximum Plasma Concentration (Cmax) of Total Antibody, Part 1 and Part 2: Plasma Trough Concentration (Ctrough) of Total Antibody, Part 1 and Part 2: Apparent Terminal Half-life (t1/2) of Total Antibody, Part 1 and Part 2: AUC of Antibody-Drug Conjugate (ADC), Part 1 and Part 2: Cmax of Antibody-Drug Conjugate (ADC), Part 1 and Part 2: Ctrough of Antibody-Drug Conjugate (ADC), Part 1 and Part 2: t1/2 of Antibody-Drug Conjugate (ADC), Part 1 and Part 2: AUC of Monomethyl Auristatin E (MMAE), Part 1 and Part 2: Cmax of Monomethyl Auristatin E (MMAE), Part 1 and Part 2: Ctrough of Monomethyl Auristatin E (MMAE), Part 1 and Part 2: t1/2 of Monomethyl Auristatin E (MMAE), Part 2: Number of Participants Who Experience One or More Adverse Events (AEs), Part 2: Number of Participants Who Discontinue Study Treatment Due to AEs, Part 2: Number of Participants Who Receive Dose Modification Due to AEs, Part 1 and Part 2: Incidence of Antidrug antibodies (ADAs) to Zilovertamab Vedotin, Part 1 and Part 2: Duration of Response (DOR), Part 1 and Part 2: Percentage of Participants with DLBCL/Burkitt Lymphoma Who Receive Stem Cell Transplant (SCT), Part 1 and Part 2: Percentage of Participants with B-ALL Who Receive SCT, Part 1 and Part 2: Percentage of Participants with B-ALL Who Receive Chimeric Antigen Receptor T (CAR-T)

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Belgium, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Slovakia, Spain, Sweden